Objective To investigate the relationship between rs1067 polymorphism of WD repeat domain(WDR)5B gene and traditional Chinese medicine(TCM)syndromes and clinical markers of ischemic stroke(IS).Methods A total of 1 567 patients with IS and healthy controls at the same time were selected.The genotyping of WDR5B gene rs1067 polymorphism was primarily per-formed with the sequenom MassARRAY SNP technology.The TCM syndromes of IS patients were classified according to the TCM Syn-drome Differentiation Diagnostic Criteria for Apoplexy.Results WDR5B gene rs1067 polymorphism was significantly associated with the occurrence of wind syndrome of IS[allelic(A/G):P=0.037;dominant(AA+GA/GG):P=0.043;additive(AA/GG):P=0.041].After adjusting for sex and age,WDR5B gene rs1067 polymorphism was still significantly associated with the risk of IS syndrome[dominant(AA+GA/GG):P=0.032;additive(AA/GG):P=0.032].After adjusting for sex and age,WDR5B gene rs1067 poly-morphism was significantly associated with postprandial 2 h plasma glucose level and high-density lipoprotein level in patients with IS(P<0.05).Conclusions WDR5B gene rs1067 polymorphism might affect the occurrence of wind syndrome of IS.WDR5B rs1067 gene polymorphism might affect postprandial 2 h plasma glucose level and high-density lipoprotein level in IS patients.

目的 旨在探讨早期生长反应因子3基因(EGR3)rs11136094多态性与缺血性脑卒中(IS)中医证候的相关性.方法 纳入病例组774例IS患者、对照组793例健康体检人群.采用《中风病辨证诊断标准(试行)》对IS患者进行中医辨证.运用MassarraySNP基因分型实验技术进行基因分型.运用PLINK软件和SPSS19.0软件进行统计分析.结果 校正年龄、性别后,EGR3基因rs11136094多态性与IS风证的发生风险显著相关﹝加性模型:OR(95％CI)=0.82(0.68～0.99),P=0.041;隐性模型:OR(95％CI)=0.67(0.49～0.91),P=0.010;EGR3基因rs11136094多态性与IS风证评分的关联具有统计学意义﹝隐性模型:β(95％CI)=-0.81(-1.49～-0.13),P=0.019﹞;rs11136094多态性与IS风证患者的血小板(PLT)水平显著相关﹝隐性模型:β=(95％CI)=24.68(4.37～44.99),P=0.018﹞.结论 EGR3基因rs11136094遗传多态性可能影响IS风证的发生发展.

目的 观察眩晕汤联合甲磺酸倍他司汀片治疗良性阵发性位置性眩晕(BPPV)手法复位后残留眩晕的临床效果.方法 选择90例BPPV手法复位后残留眩晕的患者,将其随机分成3组,每组30例.A组给予甲磺酸倍他司汀片治疗,B组给予眩晕汤治疗,C组给予眩晕汤联合甲磺酸倍他司汀片治疗.3组患者均连续治疗14d.观察3组患者治疗3d、7d后的临床疗效,治疗前1d、治疗7d和14d后的眩晕障碍量表(DHI)评分,以及治疗后1个月、3个月、6个月的复发情况.结果 治疗3 d后,B组和C组的临床疗效均优于A组;治疗7 d后,C组的临床疗效优于A组和B组,而B组优于A组(均P<0.05).治疗7 d、14 d后,DHI得分均A组>B组>C组(均P<0.05).治疗后1个月、3个月及6个月,C组的复发率均低于A组和B组(均P<0.05).结论 眩晕汤联合甲磺酸倍他司汀片治疗BPPV手法复位后残留眩晕的临床效果显著,与单一药物治疗相比,其可更好地改善患者的头晕症状,降低复发率,值得临床推广.

目的 研究旨在探讨中国汉族人群中lncRNA SH3BP5-AS1多态性rs11713836与缺血性中风(ischemic stroke,IS)遗传易感性及中医证候的关系.方法 研究包括774例IS患者和793例对照组.采用Massarray SNP基因分型方法进行基因分型.采用《中风病中医辨证诊断标准》量表对IS患者进行中医证候鉴定.所有统计分析采用SPSS 17.0统计软件进行.结果 在隐性模型下,lncRNA SH3BP5-AS1多态性rs11713836与缺血性中风血瘀证显著相关[OR(95％CI)=0.52(0.29-0.93),P=0.028],在校正了包括性别和年龄在内的协变量后,结果依然有统计学意义;而rs11713836与缺血性中风易感性及风、痰、火热、气虚证等中医证候易感性无相关性.此外,rs11713836与血清APO-B[隐性模型:OR(95％CI)=0.09(0.02-0.17),P=0.032]、VLDL[加性模型:OR(95％CI)=0.09(0.04-0.14),P＜0.001;显性模型:OR(95％CI)=0.09(0.02-0.16),P=0.011;隐性模型:OR(95％CI)=0.19(0.09-0.30),P＜0.001]、TG[加性模型:OR(95％CI)=0.15(0.05-0.24),P=0.003;显性模型:OR(95％CI)=0.14(0.01-0.27),P=0.041;隐性模型:OR(95％CI)=0.31(0.11-0.50),P=0.003]、FIB[显性模型:OR(95％CI)=0.20(0.04-0.35),P=0.012]显著相关,调整性别年龄后以上关联依然有统计学意义.结论 lncRNA SH3BP5-AS1多态性rs11713836可能影响缺血性中风血瘀证的发生,有望作为缺血性中风血瘀证的生物标志物与潜在治疗靶点,并且可能影响缺血性中风患者的血脂代谢和凝血功能.